Next Article in Journal
A Research on the Classification and Applicability of the Mobile Health Applications
Previous Article in Journal
“Balancing Expectations with Actual Realities”: Conversations with Clinicians and Scientists in the First Year of a High-Risk Childhood Cancer Precision Medicine Trial
Open AccessReview

HER2 Heterogeneity in Personalized Therapy of Gastro-Oesophageal Malignancies: An Overview by Different Methodologies

1
Department of Human Pathology in Adult and Developmental Age “Gaetano Barresi”, Section of Pathology, University of Messina, 98125 Messina, Italy
2
Department of Medicine and Surgery, University of Salerno, 84131 Salerno, Italy
*
Author to whom correspondence should be addressed.
J. Pers. Med. 2020, 10(1), 10; https://doi.org/10.3390/jpm10010010
Received: 9 December 2019 / Revised: 6 February 2020 / Accepted: 12 February 2020 / Published: 21 February 2020
Human epidermal growth factor receptor-2 (HER2)-expression gastro-oesophageal adenocarcinomas (GEA) gained interest as an important target for therapy with trastuzumab. In the current review, we focused the current knowledge on HER2 status in dysplastic and neoplastic gastric conditions, analyzing the methodological procedures to identify HER2 expression/amplification, as well as the proposed scoring recommendations. One of the most relevant questions to evaluate the useful impact of HER2 status on therapeutic choice in GEAs is represented by the significant heterogeneity of HER2 protein and gene expression that may affect the targeted treatment selection. Future development of biotechnology will continue to evolve in order to offer more powerful detection systems for the assessment of HER2 status. Finally, liquid biopsy as well as mutation/amplification of several additional genes may furnish an early detection of secondary HER2 resistance mechanisms in GEAs with a better monitoring of the treatment response. View Full-Text
Keywords: human epidermal growth factor receptor 2 (HER2); immunohistochemistry; dysplasia; gastric cancer; neoplastic heterogeneity; liquid biopsy human epidermal growth factor receptor 2 (HER2); immunohistochemistry; dysplasia; gastric cancer; neoplastic heterogeneity; liquid biopsy
Show Figures

Figure 1

MDPI and ACS Style

Ieni, A.; Cardia, R.; Pizzimenti, C.; Zeppa, P.; Tuccari, G. HER2 Heterogeneity in Personalized Therapy of Gastro-Oesophageal Malignancies: An Overview by Different Methodologies. J. Pers. Med. 2020, 10, 10.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop